Sign up Australia
Proactive Investors - Run By Investors For Investors

AstraZeneca reports positive top-line data from phase III COPD trial

The KRONOS trial showed that Astra’s PT010 inhaler can improve lung function in patients with moderate to severe chronic obstructive pulmonary disease
Respiratory is a key area of focus for AstraZeneca

AstraZeneca PLC (LON:AZN) has reported positive top-line data from a phase III trial which compared its PT010 therapy for chronic obstructive pulmonary disease (COPD) against existing treatments.

The FTSE 100 drugmaker said its triple combination inhaler “demonstrated a statistically significant improvement” in eight of the nine lung function primary endpoints compared with dual combo therapies.

READ: Immuno-oncology: What does 2018 have in store for Big Pharma and their cancer immunotherapies?

COPD is a common condition that mainly affects middle-aged or older adults who smoke and can block airflow to the lungs causing breathing difficulties.

Astra added that no unexpected safety or tolerability signals for PT010 were identified in the trial.

Regulatory submissions in Japan and China are expected in the second half of this year, followed by potential submissions in the US and Europe in 2019.

“We are encouraged by the results of the KRONOS trial that has demonstrated PT010's efficacy in improving lung function and look forward to the ETHOS exacerbation trial results in 2019 that will further characterise the role of this potential treatment for patients with COPD,” said chief medical officer Sean Bohen.

READ: AstraZeneca gets approval for two cancer and asthma treatments in Japan

Professor Kalus Rabe, the co-ordinating investigator of the trial, said: “With the KRONOS trial, we are seeing the potential of PT010 as a triple combination therapy for COPD.

“I expect the triple class of medicines to play an increasingly important role in addressing the needs of the many COPD patients who are currently undertreated or are receiving triple combination therapy as separate medicines in multiple devices.”

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety
Callitas CEO James Thompson
July 21 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
July 03 2018
The research and diagnostic company develops cancer-detecting blood tests

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use